KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Non-Current Assets for 12 consecutive years, with $17.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $17.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $17.4 million, a N/A change, with the full-year FY2024 number at $17.4 million, changed N/A from a year prior.
  • Other Non-Current Assets was $17.4 million for Q4 2024 at Halozyme Therapeutics, down from $52.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $52.5 million in Q2 2024 to a low of $500000.0 in Q2 2020.
  • A 4-year average of $11.7 million and a median of $2.1 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: changed 0.0% in 2020, then surged 2996.2% in 2021.
  • Halozyme Therapeutics' Other Non-Current Assets stood at $500000.0 in 2020, then changed by 0.0% to $500000.0 in 2021, then changed by 0.0% to $500000.0 in 2022, then surged by 3380.0% to $17.4 million in 2024.
  • Per Business Quant, the three most recent readings for HALO's Other Non-Current Assets are $17.4 million (Q4 2024), $52.5 million (Q2 2024), and $500000.0 (Q4 2022).